Korro Bio, Inc. (KRRO) - Net Assets
Based on the latest financial reports, Korro Bio, Inc. (KRRO) has net assets worth $119.63 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($183.62 Million) and total liabilities ($63.99 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Korro Bio, Inc. (KRRO) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $119.63 Million |
| % of Total Assets | 65.15% |
| Annual Growth Rate | N/A |
| 5-Year Change | -60.68% |
| 10-Year Change | N/A |
| Growth Volatility | 67.22 |
Korro Bio, Inc. - Net Assets Trend (2017–2025)
This chart illustrates how Korro Bio, Inc.'s net assets have evolved over time, based on quarterly financial data. Also explore Korro Bio, Inc. assets under control for the complete picture of this company's asset base.
Annual Net Assets for Korro Bio, Inc. (2017–2025)
The table below shows the annual net assets of Korro Bio, Inc. from 2017 to 2025. For live valuation and market cap data, see market cap of Korro Bio, Inc..
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $51.44 Million | -67.93% |
| 2024-12-31 | $160.41 Million | -5.59% |
| 2023-12-31 | $169.91 Million | +271.57% |
| 2022-12-31 | $-99.03 Million | -175.70% |
| 2021-12-31 | $130.82 Million | -32.04% |
| 2020-12-31 | $192.49 Million | +15.02% |
| 2019-12-31 | $167.36 Million | +476.01% |
| 2018-12-31 | $-44.51 Million | -50.16% |
| 2017-12-31 | $-29.64 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Korro Bio, Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 35392600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $9.00K | 0.02% |
| Other Comprehensive Income | $212.00K | 0.41% |
| Other Components | $435.06 Million | 845.79% |
| Total Equity | $51.44 Million | 100.00% |
Korro Bio, Inc. Competitors by Market Cap
The table below lists competitors of Korro Bio, Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Yatsen Holding
NYSE:YSG
|
$165.34 Million |
|
A Paradise Acquisition Corp.
NYSE:APAD
|
$165.42 Million |
|
Oriola-KD Oyj B
HE:OKDBV
|
$165.45 Million |
|
LAUNCH TECH CO. H YC-01
F:LAN
|
$165.68 Million |
|
AMA Group Ltd
AU:AMA
|
$165.23 Million |
|
STLLR Gold Inc.
TO:STLR
|
$165.16 Million |
|
Jalles Machado S/A
SA:JALL3
|
$165.08 Million |
|
MIRC Electronics Limited
NSE:MIRCELECTR
|
$165.07 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Korro Bio, Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 160,415,000 to 51,439,000, a change of -108,976,000 (-67.9%).
- Net loss of 117,260,000 reduced equity.
- Other comprehensive income decreased equity by 56,000.
- Other factors increased equity by 8,340,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-117.26 Million | -227.96% |
| Other Comprehensive Income | $-56.00K | -0.11% |
| Other Changes | $8.34 Million | +16.21% |
| Total Change | $- | -67.93% |
Book Value vs Market Value Analysis
This analysis compares Korro Bio, Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.12x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $-47.27 | $11.61 | x |
| 2018-12-31 | $-76.99 | $11.61 | x |
| 2019-12-31 | $271.29 | $11.61 | x |
| 2020-12-31 | $298.41 | $11.61 | x |
| 2021-12-31 | $29.42 | $11.61 | x |
| 2022-12-31 | $-388.09 | $11.61 | x |
| 2023-12-31 | $111.10 | $11.61 | x |
| 2024-12-31 | $17.98 | $11.61 | x |
| 2025-12-31 | $5.47 | $11.61 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Korro Bio, Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -227.96%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1834.48%
- • Asset Turnover: 0.06x
- • Equity Multiplier: 2.21x
- Recent ROE (-227.96%) is below the historical average (-46.39%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-17.27 Million |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-14.34 Million |
| 2019 | -11.20% | -64.76% | 0.13x | 1.33x | $-35.48 Million |
| 2020 | -13.77% | -71.68% | 0.14x | 1.38x | $-45.76 Million |
| 2021 | -64.73% | -601.98% | 0.08x | 1.42x | $-97.77 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-48.13 Million |
| 2023 | -47.77% | 0.00% | 0.00x | 1.30x | $-98.16 Million |
| 2024 | -52.10% | -3680.36% | 0.01x | 1.41x | $-99.62 Million |
| 2025 | -227.96% | -1834.48% | 0.06x | 2.21x | $-122.40 Million |
Industry Comparison
This section compares Korro Bio, Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $173,871,658
- Average return on equity (ROE) among peers: -26.52%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Korro Bio, Inc. (KRRO) | $119.63 Million | 0.00% | 0.53x | $165.28 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $98.85 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $1.59 Billion |
| Abeona Therapeutics Inc (ABEO) | $134.04 Million | -42.28% | 0.30x | $309.44 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $181.29 Million |
| Abpro Holdings, Inc. (ABP) | $-75.73 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $189.45 Million | -60.80% | 0.14x | $795.12 Million |
| Arbutus Biopharma Corp (ABUS) | $200.23 Million | -28.52% | 0.14x | $854.72 Million |
| ABVC Biopharma Inc (ABVC) | $-5.75 Million | 0.00% | 0.00x | $27.18 Million |
| Abivax SA American Depositary Shares (ABVX) | $56.72 Million | -25.23% | 0.07x | $9.67 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $52.99 Million | -121.23% | 0.22x | $3.61 Billion |
About Korro Bio, Inc.
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia. It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate … Read more